Quality Criteria Establishment for Dissolution of Ascorbic Acid from Sustained Release Pellets by Mostafa Essam Ahmed Mostafa Eissa in Nutrition and food science open access journal
This document discusses the new quality paradigm in pharmaceuticals which emphasizes building quality in from the beginning through a systematic quality by design (QbD) approach. It outlines the key elements of QbD including establishing a quality target product profile, identifying critical quality attributes, understanding material attributes and process parameters that impact critical quality attributes through risk assessment, developing a design space, and implementing a control strategy. The new paradigm focuses on science-based approaches, quality risk management, robust quality systems, and an integrated approach across the product lifecycle between industry and regulators.
Significant advances in analytical technology over the past few years have improved the quantification and characterization capabilities for subvisible ( 1 - 100 μm) and submicron particles (≤1 μm). As the technology continues to improve so do the expectations of regulatory agencies for sponsors to characterize particles in these size ranges. However, multiple orthogonal methods are required to span the entire range and accurately characterize the particle profile. Each instrument has its own limitations based on detection method and properties of therapeutic protein products that must be well understood to generate high-quality data. Written by Amber Fradkin, Ph.D. Associate Director, R&D, KBI Biopharma
The document discusses Quality by Design (QbD) guidelines from the International Council for Harmonisation (ICH). It describes the key parts of the ICH Q8 guidelines, including pharmaceutical development, quality target product profiles, critical quality attributes, risk assessment, design space, and control strategy. The guidelines provide a systematic approach to developing pharmaceutical products and processes based on sound science and quality risk management. Regulatory agencies support QbD as it can facilitate innovation and streamline product approval and changes.
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) deliveryMerck Life Sciences
We will introduce an excipient platform that makes it possible to combine excipients in ways that can reduce protein viscosity to a greater extent.
*About challenges arising from high concentrated protein formulations
*The Viscosity reduction Platform: A portfolio of excipients to manage protein viscosity
*Impact of viscosity reducing excipient use on protein stability
*Impact of protein viscosity on syringeability
This document discusses bioanalytical method validation. It defines a bioanalytical method as procedures for collecting, processing, storing, and analyzing a biological matrix for a chemical compound. Bioanalytical method validation establishes that a quantitative analytical method is suitable for biomedical use. The document outlines the key steps in method validation including linearity, selectivity, accuracy, reproducibility, stability, and ruggedness. It provides guidelines on bioanalytical method validation from regulatory agencies like the USFDA.
Addressing Downstream Challenges with Complex InjectablesMerck Life Sciences
The complex injectable market is gaining traction in the injectable therapies, however manufacturing of it is critical. In this webinar, lets brainstorm on the downstream criticalities of these molecules and how to handle the same.
This document provides an overview of Quality by Design (QbD) in pharmaceutical development based on ICH Q8 guidelines. It discusses key QbD concepts like critical quality attributes, risk assessment, design space and control strategy. It also presents two case studies applying QbD approaches - one on developing controlled-release felodipine tablets using polymeric surfactants and another on starch-based nanocapsules for topical drug delivery. The document outlines the various elements of pharmaceutical development as defined in ICH Q8 like quality target product profile, critical quality attributes, risk assessment, design space and product lifecycle management.
This document discusses the new quality paradigm in pharmaceuticals which emphasizes building quality in from the beginning through a systematic quality by design (QbD) approach. It outlines the key elements of QbD including establishing a quality target product profile, identifying critical quality attributes, understanding material attributes and process parameters that impact critical quality attributes through risk assessment, developing a design space, and implementing a control strategy. The new paradigm focuses on science-based approaches, quality risk management, robust quality systems, and an integrated approach across the product lifecycle between industry and regulators.
Significant advances in analytical technology over the past few years have improved the quantification and characterization capabilities for subvisible ( 1 - 100 μm) and submicron particles (≤1 μm). As the technology continues to improve so do the expectations of regulatory agencies for sponsors to characterize particles in these size ranges. However, multiple orthogonal methods are required to span the entire range and accurately characterize the particle profile. Each instrument has its own limitations based on detection method and properties of therapeutic protein products that must be well understood to generate high-quality data. Written by Amber Fradkin, Ph.D. Associate Director, R&D, KBI Biopharma
The document discusses Quality by Design (QbD) guidelines from the International Council for Harmonisation (ICH). It describes the key parts of the ICH Q8 guidelines, including pharmaceutical development, quality target product profiles, critical quality attributes, risk assessment, design space, and control strategy. The guidelines provide a systematic approach to developing pharmaceutical products and processes based on sound science and quality risk management. Regulatory agencies support QbD as it can facilitate innovation and streamline product approval and changes.
The Viscosity Reduction Platform: Enabling subcutaneous (subQ) deliveryMerck Life Sciences
We will introduce an excipient platform that makes it possible to combine excipients in ways that can reduce protein viscosity to a greater extent.
*About challenges arising from high concentrated protein formulations
*The Viscosity reduction Platform: A portfolio of excipients to manage protein viscosity
*Impact of viscosity reducing excipient use on protein stability
*Impact of protein viscosity on syringeability
This document discusses bioanalytical method validation. It defines a bioanalytical method as procedures for collecting, processing, storing, and analyzing a biological matrix for a chemical compound. Bioanalytical method validation establishes that a quantitative analytical method is suitable for biomedical use. The document outlines the key steps in method validation including linearity, selectivity, accuracy, reproducibility, stability, and ruggedness. It provides guidelines on bioanalytical method validation from regulatory agencies like the USFDA.
Addressing Downstream Challenges with Complex InjectablesMerck Life Sciences
The complex injectable market is gaining traction in the injectable therapies, however manufacturing of it is critical. In this webinar, lets brainstorm on the downstream criticalities of these molecules and how to handle the same.
This document provides an overview of Quality by Design (QbD) in pharmaceutical development based on ICH Q8 guidelines. It discusses key QbD concepts like critical quality attributes, risk assessment, design space and control strategy. It also presents two case studies applying QbD approaches - one on developing controlled-release felodipine tablets using polymeric surfactants and another on starch-based nanocapsules for topical drug delivery. The document outlines the various elements of pharmaceutical development as defined in ICH Q8 like quality target product profile, critical quality attributes, risk assessment, design space and product lifecycle management.
This document summarizes ICH Q8 guidelines on pharmaceutical development. It outlines the key components of drug development, including drug substances, excipients, formulation development, manufacturing process development, container closure systems, and compatibility studies. The objectives of Q8 are to design a quality product and manufacturing process using scientific approaches and quality risk management. It advocates moving from quality by testing to quality by design to build quality in from the beginning and continuously improve through the product lifecycle.
Incorporating Mechanistic Modeling & Simulation to Assist with Formulation De...Simulations Plus, Inc.
Overview of Mechanistic Simulation Models
Predicting in vivo absorption & PK
Applications in Generic Product Development
Generating IVIVCs
Performing virtual bioequivalence trials and establishing dissolution specifications
Understanding food effects
Scale of Science In Pharmaceutical Developmentsatenvish
This document discusses pre-formulation studies in pharmaceutical development. It begins by welcoming the audience and introducing Christopher Lipinski and his influential "Rule of Five" for drug candidate screening. It then provides an overview of the scale of science involved in pre-formulation and early process development activities. Several key aspects of pre-formulation are examined in more detail, including Lipinski's Rule of Five analysis, challenges in dosage form development, influencing parameters, and characteristics of ideal drug candidates. The objectives and components of pre-formulation are outlined.
Medicinal products must comply with their approved specifications before they are released into the market. Compliance with release specifications can be demonstrated by performing a complete set of tests on the active substance and/or finished product, according to the approved specifications. Under certain conditions, an alternative strategy to systematic end product testing is possible. So far this concept has been mainly applied to sterility testing of terminally sterilised products and has become associated with parametric release applications. Recent guidelines adopted in the ICH context (ICH Q8, Q9 and Q10) have made it possible to apply a similar release decision process to tests other than sterility, this approach has been called Real Time Release Testing (RTRT).
RTRT is a system of release that gives assurance that the product is of intended quality, based on the information collected during the manufacturing process, through product knowledge and on process understanding and control. RTRT recognises that under specific circumstances an appropriate combination of process controls (critical process parameters) together with pre-defined material attributes may provide greater assurance of product quality than end-product testing and the context as such be an integral part of the control strategy. The RTRT principle is already authorised for use as an optional alternative to routine sterility testing of products terminally sterilised in their final container i.e. parametric release. Enhanced product knowledge and process understanding, the use of quality risk management principles and the application of an appropriate pharmaceutical quality system, as defined within ICH Q8,Q9 and Q10 provide the platform for establishing RTRT mechanisms for other applications, for new products as well as established marketed products. Release of a product can be a combination of a RTR approach for certain critical quality attributes (CQAs) and a more conventional evaluation for other CQAs (partial RTR).
This presentation deals with the concepts of Real Time Release Testing. This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web.
IRJET - Design and Evaluation of Albendazole Sustained Release TabletsIRJET Journal
This document describes the design and evaluation of albendazole sustained release tablets. Three tablet formulations were prepared (A1-A3) using different polymer blends of HPMC K4M, Carbopol 934, and hydroxyethyl cellulose in a 1:1 ratio. The tablets were evaluated for hardness, weight variation, friability, content uniformity, disintegration time, and in-vitro drug release. Formulation A3 displayed the best sustained release profile with a t50% of 6-7 hours and t80% of 10-12 hours. The release kinetics followed zero-order or Higuchi models, indicating drug release through swelling and erosion of the matrix tablets. Overall, the formulations
The document discusses the Quality by Design (QbD) approach to pharmaceutical development according to ICH Q8 Annex. It outlines the key steps in QbD, including defining target product profiles, critical quality attributes, risk assessment, design space, control strategy, and continual improvement. QbD emphasizes developing a systematic understanding of products and processes based on science and risk management to ensure quality.
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...KBI Biopharma
This document discusses using the ProteinSimple Maurice system with Empower control software for analyzing proteins. It provides an overview of KBI Biopharma's analytical services and locations. It then describes the Maurice system and Empower software, highlighting how the software can be used to analyze charge heterogeneity, pI, purity and size of proteins from Maurice runs. It also notes some calculations that may need to be done in Excel if the Empower software does not automatically provide certain analysis values.
The document summarizes recent initiatives by the FDA related to pharmaceutical quality and process validation. It discusses the Critical Path Initiative, ICH Q8, Q9, and Q10 guidelines, revisions to CGMP regulations, FDA's quality system guidance, process validation approaches, and progress implementing process analytical technologies. It also notes some remaining challenges around process monitoring and validation, and data evaluation.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Quality by design in pharmaceutical developmentSHUBHAMGWAGH
This document provides an overview of quality by design (QbD) in pharmaceutical development. It discusses the benefits of QbD including eliminating batch failures and ensuring a better designed product. The key aspects of QbD include establishing a quality target product profile, identifying critical quality attributes, performing a risk assessment, defining a design space, describing a control strategy, and enabling continuous improvement through life cycle management. QbD aims to build quality into the product design and manufacturing process through a systematic and scientific approach.
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3FKGUH6
At the high protein concentrations required for subcutaneous administration, protein formulations often become highly viscous. In this webinar, Dr. Tobias Rosenkranz will introduce a new approach that combines different excipients to reduce viscosity and discuss synergistic effects.
Subcutaneous (subQ) administration can improve patient convenience and reduce healthcare costs by avoiding the need for hospitalization. Yet in some cases, high protein concentrations make formulations far more viscous, prohibiting this route of administration. While viscosity can normally be reduced by using certain excipients, merely adding more and more of a single excipient may not bring sufficient improvement and can even compromise protein stability. This webinar will introduce an excipient platform that makes it possible to combine excipients in ways that can reduce protein viscosity to a greater extent.
In this webinar, you will learn about:
• Challenges arising from high concentrated protein formulations
• The viscosity reduction platform: a portfolio of excipients to manage protein viscosity
• The impact of viscosity reducing excipients on protein stability
• The impact of protein viscosity on syringability
Presented by: Tobias Rosenkranz, Ph.D., Senior Manager, Biomolecule Formulation R&D
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentMilliporeSigma
Watch the webinar here: http://bit.ly/PEGsWebinar
As the field of antibody-drug conjugation chemistry has advanced, the use of linkers to impart "drugability" has also been growing. Recent literature shows a variety of linear and branched monodisperse PEGs being called on to modify the PK/PD profile of some of the most active but lipophilic payloads. In this webinar, we will survey the types of PEGs that are used in ADCs and give examples of successful implementation to change the biophysical properties of the construct. In addition, we will focus on PEGs and why activated PEGs are widely used to improve the pharmacokinetics of drugs (such as pegylated proteins, peptides etc.). Raw materials used in this field may have a variety of polydispersity. However, when it comes to the use of activated PEGs as linkers for ADCs, the requirements are significantly higher. Therefore, the choice and control of the PEG linker is crucial for the successful development and accelerated time to market for your ADC.
This webinar addresses critical success factors such as:
• Survey of current PEG enhanced ADCs
• Why PEGs are used designing ADCs
• Critical parameters for aPEGs used as linkers
• Requirements in terms of analytical capabilities
Nextar ChemPharma Solutions provides integrated contract drug development and manufacturing services. They have over 35 experienced employees working in state-of-the-art laboratories and clean rooms. Their services include custom synthesis, formulation development, analytical testing, and GMP manufacturing of clinical trial materials. Nextar has successfully completed over 650 projects for 150 customers, developing over 50 innovative formulations and manufacturing over 25 products for clinical trials.
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final ReviewedBrent Hilker
Current methods for targeted drug delivery using enteric capsules face challenges including capsule leakage and breakage in the stomach. Researchers tested enteric capsules and enteric coated capsules containing a dye formulation using in vitro dissolution tests and a dynamic gastric model. The enteric capsules showed some dye leakage in the stomach while the enteric coated capsules performed better. However, in the dynamic gastric model the enteric capsules ruptured in the fasted state due to shear forces, while maintaining integrity in the fed state with reduced forces. Formulation optimization and advising patients to take capsules with food may improve enteric capsule performance.
The document discusses process analytical chemistry, which involves applying analytical chemistry techniques to chemical processes for quality control and production monitoring. It provides an introduction to process analytical chemistry, outlines its importance for obtaining real-time process measurements, and notes some of its applications in industries like pharmaceutical manufacturing. The document also discusses related topics like process analytical technology and on-line monitoring.
Stability indicating analytical method development and validation for estimat...SriramNagarajan18
Stability indicating analytical method development and validation for estimation of Ceftazidime and Avibactam in bulk and pharmaceutical dosage form using RP-HPLC
1. Stabicon provides formulation development and analytical testing services for various drug delivery systems including oral, ophthalmic, urogenital, rectal, and dermal formulations.
2. Services include brand extension formulation, in vitro drug testing programs, delivery enhancement technology development, formulation reverse engineering, and antimicrobial screening.
3. Stabicon operates a centralized stability testing center and provides analytical and microbiology support services for medical devices and vaccines to ensure product quality over time.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the target protein efficiently and economically with a straightforward method.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the protein efficiently and economically while maintaining activity.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the target protein efficiently and economically with a straightforward method.
This document provides an overview of pharmaceutical development based on the ICH Q8(R2) guideline. It discusses key concepts like the quality target product profile, critical quality attributes, risk assessment, design space, and control strategy. The presentation was given by Dr. Jean-Louis Robert at an ICH-GCG ASEAN conference in Kuala Lumpur, Malaysia, where he discussed these concepts, provided examples, and emphasized building quality into products through a systematic and science-based development approach.
This document summarizes ICH Q8 guidelines on pharmaceutical development. It outlines the key components of drug development, including drug substances, excipients, formulation development, manufacturing process development, container closure systems, and compatibility studies. The objectives of Q8 are to design a quality product and manufacturing process using scientific approaches and quality risk management. It advocates moving from quality by testing to quality by design to build quality in from the beginning and continuously improve through the product lifecycle.
Incorporating Mechanistic Modeling & Simulation to Assist with Formulation De...Simulations Plus, Inc.
Overview of Mechanistic Simulation Models
Predicting in vivo absorption & PK
Applications in Generic Product Development
Generating IVIVCs
Performing virtual bioequivalence trials and establishing dissolution specifications
Understanding food effects
Scale of Science In Pharmaceutical Developmentsatenvish
This document discusses pre-formulation studies in pharmaceutical development. It begins by welcoming the audience and introducing Christopher Lipinski and his influential "Rule of Five" for drug candidate screening. It then provides an overview of the scale of science involved in pre-formulation and early process development activities. Several key aspects of pre-formulation are examined in more detail, including Lipinski's Rule of Five analysis, challenges in dosage form development, influencing parameters, and characteristics of ideal drug candidates. The objectives and components of pre-formulation are outlined.
Medicinal products must comply with their approved specifications before they are released into the market. Compliance with release specifications can be demonstrated by performing a complete set of tests on the active substance and/or finished product, according to the approved specifications. Under certain conditions, an alternative strategy to systematic end product testing is possible. So far this concept has been mainly applied to sterility testing of terminally sterilised products and has become associated with parametric release applications. Recent guidelines adopted in the ICH context (ICH Q8, Q9 and Q10) have made it possible to apply a similar release decision process to tests other than sterility, this approach has been called Real Time Release Testing (RTRT).
RTRT is a system of release that gives assurance that the product is of intended quality, based on the information collected during the manufacturing process, through product knowledge and on process understanding and control. RTRT recognises that under specific circumstances an appropriate combination of process controls (critical process parameters) together with pre-defined material attributes may provide greater assurance of product quality than end-product testing and the context as such be an integral part of the control strategy. The RTRT principle is already authorised for use as an optional alternative to routine sterility testing of products terminally sterilised in their final container i.e. parametric release. Enhanced product knowledge and process understanding, the use of quality risk management principles and the application of an appropriate pharmaceutical quality system, as defined within ICH Q8,Q9 and Q10 provide the platform for establishing RTRT mechanisms for other applications, for new products as well as established marketed products. Release of a product can be a combination of a RTR approach for certain critical quality attributes (CQAs) and a more conventional evaluation for other CQAs (partial RTR).
This presentation deals with the concepts of Real Time Release Testing. This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web.
IRJET - Design and Evaluation of Albendazole Sustained Release TabletsIRJET Journal
This document describes the design and evaluation of albendazole sustained release tablets. Three tablet formulations were prepared (A1-A3) using different polymer blends of HPMC K4M, Carbopol 934, and hydroxyethyl cellulose in a 1:1 ratio. The tablets were evaluated for hardness, weight variation, friability, content uniformity, disintegration time, and in-vitro drug release. Formulation A3 displayed the best sustained release profile with a t50% of 6-7 hours and t80% of 10-12 hours. The release kinetics followed zero-order or Higuchi models, indicating drug release through swelling and erosion of the matrix tablets. Overall, the formulations
The document discusses the Quality by Design (QbD) approach to pharmaceutical development according to ICH Q8 Annex. It outlines the key steps in QbD, including defining target product profiles, critical quality attributes, risk assessment, design space, control strategy, and continual improvement. QbD emphasizes developing a systematic understanding of products and processes based on science and risk management to ensure quality.
Data Collection on the ProteinSimple Maurice: Driving Compliance with the Emp...KBI Biopharma
This document discusses using the ProteinSimple Maurice system with Empower control software for analyzing proteins. It provides an overview of KBI Biopharma's analytical services and locations. It then describes the Maurice system and Empower software, highlighting how the software can be used to analyze charge heterogeneity, pI, purity and size of proteins from Maurice runs. It also notes some calculations that may need to be done in Excel if the Empower software does not automatically provide certain analysis values.
The document summarizes recent initiatives by the FDA related to pharmaceutical quality and process validation. It discusses the Critical Path Initiative, ICH Q8, Q9, and Q10 guidelines, revisions to CGMP regulations, FDA's quality system guidance, process validation approaches, and progress implementing process analytical technologies. It also notes some remaining challenges around process monitoring and validation, and data evaluation.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Quality by design in pharmaceutical developmentSHUBHAMGWAGH
This document provides an overview of quality by design (QbD) in pharmaceutical development. It discusses the benefits of QbD including eliminating batch failures and ensuring a better designed product. The key aspects of QbD include establishing a quality target product profile, identifying critical quality attributes, performing a risk assessment, defining a design space, describing a control strategy, and enabling continuous improvement through life cycle management. QbD aims to build quality into the product design and manufacturing process through a systematic and scientific approach.
The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) DeliveryMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3FKGUH6
At the high protein concentrations required for subcutaneous administration, protein formulations often become highly viscous. In this webinar, Dr. Tobias Rosenkranz will introduce a new approach that combines different excipients to reduce viscosity and discuss synergistic effects.
Subcutaneous (subQ) administration can improve patient convenience and reduce healthcare costs by avoiding the need for hospitalization. Yet in some cases, high protein concentrations make formulations far more viscous, prohibiting this route of administration. While viscosity can normally be reduced by using certain excipients, merely adding more and more of a single excipient may not bring sufficient improvement and can even compromise protein stability. This webinar will introduce an excipient platform that makes it possible to combine excipients in ways that can reduce protein viscosity to a greater extent.
In this webinar, you will learn about:
• Challenges arising from high concentrated protein formulations
• The viscosity reduction platform: a portfolio of excipients to manage protein viscosity
• The impact of viscosity reducing excipients on protein stability
• The impact of protein viscosity on syringability
Presented by: Tobias Rosenkranz, Ph.D., Senior Manager, Biomolecule Formulation R&D
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentMilliporeSigma
Watch the webinar here: http://bit.ly/PEGsWebinar
As the field of antibody-drug conjugation chemistry has advanced, the use of linkers to impart "drugability" has also been growing. Recent literature shows a variety of linear and branched monodisperse PEGs being called on to modify the PK/PD profile of some of the most active but lipophilic payloads. In this webinar, we will survey the types of PEGs that are used in ADCs and give examples of successful implementation to change the biophysical properties of the construct. In addition, we will focus on PEGs and why activated PEGs are widely used to improve the pharmacokinetics of drugs (such as pegylated proteins, peptides etc.). Raw materials used in this field may have a variety of polydispersity. However, when it comes to the use of activated PEGs as linkers for ADCs, the requirements are significantly higher. Therefore, the choice and control of the PEG linker is crucial for the successful development and accelerated time to market for your ADC.
This webinar addresses critical success factors such as:
• Survey of current PEG enhanced ADCs
• Why PEGs are used designing ADCs
• Critical parameters for aPEGs used as linkers
• Requirements in terms of analytical capabilities
Nextar ChemPharma Solutions provides integrated contract drug development and manufacturing services. They have over 35 experienced employees working in state-of-the-art laboratories and clean rooms. Their services include custom synthesis, formulation development, analytical testing, and GMP manufacturing of clinical trial materials. Nextar has successfully completed over 650 projects for 150 customers, developing over 50 innovative formulations and manufacturing over 25 products for clinical trials.
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final ReviewedBrent Hilker
Current methods for targeted drug delivery using enteric capsules face challenges including capsule leakage and breakage in the stomach. Researchers tested enteric capsules and enteric coated capsules containing a dye formulation using in vitro dissolution tests and a dynamic gastric model. The enteric capsules showed some dye leakage in the stomach while the enteric coated capsules performed better. However, in the dynamic gastric model the enteric capsules ruptured in the fasted state due to shear forces, while maintaining integrity in the fed state with reduced forces. Formulation optimization and advising patients to take capsules with food may improve enteric capsule performance.
The document discusses process analytical chemistry, which involves applying analytical chemistry techniques to chemical processes for quality control and production monitoring. It provides an introduction to process analytical chemistry, outlines its importance for obtaining real-time process measurements, and notes some of its applications in industries like pharmaceutical manufacturing. The document also discusses related topics like process analytical technology and on-line monitoring.
Stability indicating analytical method development and validation for estimat...SriramNagarajan18
Stability indicating analytical method development and validation for estimation of Ceftazidime and Avibactam in bulk and pharmaceutical dosage form using RP-HPLC
1. Stabicon provides formulation development and analytical testing services for various drug delivery systems including oral, ophthalmic, urogenital, rectal, and dermal formulations.
2. Services include brand extension formulation, in vitro drug testing programs, delivery enhancement technology development, formulation reverse engineering, and antimicrobial screening.
3. Stabicon operates a centralized stability testing center and provides analytical and microbiology support services for medical devices and vaccines to ensure product quality over time.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the target protein efficiently and economically with a straightforward method.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the protein efficiently and economically while maintaining activity.
The document provides guidance on developing a protein purification strategy using a three phase approach - capture, intermediate purification, and polishing. It emphasizes defining objectives, understanding the target protein and contaminant properties, developing analytical assays, and limiting the number of purification steps. The goal is to purify the target protein efficiently and economically with a straightforward method.
This document provides an overview of pharmaceutical development based on the ICH Q8(R2) guideline. It discusses key concepts like the quality target product profile, critical quality attributes, risk assessment, design space, and control strategy. The presentation was given by Dr. Jean-Louis Robert at an ICH-GCG ASEAN conference in Kuala Lumpur, Malaysia, where he discussed these concepts, provided examples, and emphasized building quality into products through a systematic and science-based development approach.
This document discusses the application of Six Sigma methodology in clinical laboratories to improve quality. It defines Six Sigma and explains how it was developed from earlier statistical quality control methods. Six Sigma uses a measurement scale from 1-6 sigma to assess process error levels, with 3 sigma considered the minimum acceptable level. The document then discusses how Six Sigma methodology, including DMAIC and DMADV, can be applied in clinical labs to reduce errors. It also provides an example of using Six Sigma metrics to evaluate error levels for various analytes tested on an automated chemistry analyzer.
This document summarizes discussions from a conference on continuous biomanufacturing. Key presentations discussed Amgen's goal of 5 g/L productivity using intensified processes, and the FDA's support for continuous manufacturing. Conference participants also discussed different continuous approaches like steady-state perfusion and dynamic perfusion. Integrating upstream and downstream processes continuously is an area still needing investigation. The best approach depends on a company's existing infrastructure and product portfolio.
Industry trends are moving toward the implementation of automated PAT strategies designed to bring analytics closer to the operation, eliminate gaps in real-time process monitoring and develop a more rapid, deeper understanding of the bioprocess.
Quality Control Assessment & Comparisons with the USA Standard Values IOSRJAC
: This article aimed to generate out a quality control assessment of the performed analytical analysis, to highlight the importance of delivering quality control system independent of how these calculations are limited. Therefore, different commercial milk powder samples were analyzed for their fat, moisture and ash, and then the standard deviations were calculated, accordingly. Repeatability and reproducibility of the analysis show good results, and the comparability of the achieved results with the USA standard values presented likewise a very close acceptance range.
1) The co-op student worked at Bristol-Myers Squibb to optimize protein purification chromatography conditions and improve impurity clearance.
2) High-throughput screening was used to evaluate different buffer and resin combinations. Process conditions were optimized to separate variants and improve purity.
3) The student met project goals including developing chromatography methods, characterizing protein populations, and providing insights into improving processes. The work focused on optimizing the initial protein A capture step to reduce downstream purification needs.
This document discusses the development of chemoenzymatic processes. It notes that while biocatalysis has been used for thousands of years, it has only emerged as a powerful tool in organic synthesis in the last 15 years. Factors driving this growth include genome sequencing, enzyme engineering, fermentation technology advances, and successful manufacturing-scale application. The document outlines key steps in integrating biocatalysis into synthesis routes including screening, selection, process development, reaction engineering, product isolation, and scale up considerations. It emphasizes the importance of enzyme activity, stability and overcoming inhibition to achieve high productivity.
Alert Action and Specification Limits for Bioburden and Endotoxin - SK26Feb15...Stephan O. Krause, PhD
The document discusses setting alert and action levels for bioburden and endotoxin levels during biologics manufacturing. It describes using a quality risk management process like FMEA to establish risk-based alert and action levels during clinical and early commercial stages when historical data is limited. For later stages when more data is available, levels can be set statistically based on actual process capability and performance. The document provides an example of revising drug substance specifications and establishing alert and action levels for bioburden and endotoxin throughout development and commercial manufacturing.
The document discusses several topics related to quality assurance of drugs, including emerging trends, key recommendations, tasks for corporate quality assurance units, communication strategies, validation variations, product integrity, managing suppliers and third parties, hazard analysis and critical control points (HACCP), guidelines for applying HACCP, and good automated manufacturing practices (GAMP). Some of the main points discussed are the changing quality assurance environment and need for continuous improvement, effective communication across the organization, risk-based auditing, ensuring product validation is continuously updated, and employing quality control and validation strategies according to ICH standards.
This document discusses Quality by Design (QbD), a systematic approach to pharmaceutical development that emphasizes product and process understanding based on sound science and quality risk management. It outlines the key elements of QbD including quality target product profiles, critical quality attributes, critical material attributes, critical process parameters, design space, control strategy, and product lifecycle management. Risk assessment tools and process analytical technology are also described as important tools that can be utilized in a QbD approach.
This document discusses different quality control formats that laboratories can use to ensure accurate patient test results. It describes the benefits of consolidated multi-analyte controls that allow laboratories to reduce costs by using fewer control products and simplify the quality control process. These controls consolidate parameters into single vials containing up to 100 analytes. The document also discusses liquid ready-to-use controls as being the most convenient format that require no preparation or reconstitution. Finally, it promotes Randox quality control products and services that aim to streamline quality control testing for laboratories.
Process Automation in Pharmaceutical Industry.pptxShalakaDhikale
The document is a presentation on process automation in the pharmaceutical industry submitted for a Master's program. It discusses how automation technologies help enhance productivity in pharmaceutical development and manufacturing. The presentation covers various pharmaceutical manufacturing processes like mixing, milling, granulation and hot melt extrusion. It also describes common equipment used like fluid bed dryers and tablet compression machines. Benefits of automation include improved productivity and safety. A case study on automating a generic injectable drug manufacturing process is also summarized.
Integrated utilization of high-throughput bioreactors & high-throughput analy...KBI Biopharma
There is a strong impetus towards rapidly advancing an increasing number of novel biotherapeutics to clinical trials. However, development of cell culture processes is labor intensive and time consuming. KBI focuses on a high throughput process development (HTPD) approach using high-throughput miniaturized bioreactors and high throughput analytics that generate growth, productivity and product quality data that match those seen with classical systems. This approach enables a significant reduction in the cell culture process development timeline and costs for investigational biopharmaceuticals to reach the clinic.
Process chemistry AS PER PCI SYLLABUS FOR M.PHARMShikha Popali
pharmaceutical process chemistry is process WHERE FROM THE RESEARCH TO FINISH PRODUCT INCLUDING THE PRODUCT DEVELOPMENT AT LABORATORY LEVEL THAN PILOT PLANT WHERE THE PRODUCT IS MANUFACTURED IN 10X THAN FINAL AT 100X THAT IS SCALE UP PLANT.
Pharmaceutical Process Chemistry Presentation.pdfRAMONARICLEA1
The document discusses key aspects of process chemistry for developing an active pharmaceutical ingredient (API). It covers three main stages: chemical development, which involves selecting a synthetic route and optimizing reaction conditions; process development, which focuses on further optimization, scale-up, and technology transfer; and process support, which provides ongoing improvements. Critical factors for a successful scale-up include thorough planning, understanding differences between lab and production equipment, applying criteria like safety and throughput, and ensuring analytical, production and safety systems are in place. The overall goal is to establish a practical, efficient and compliant manufacturing process for an API.
Jetpharma implemented Quality by Design (QbD) for their micronization processes to improve process understanding and control. They conducted a case study analyzing how the micronization process influences particle size distribution (PSD), a critical quality attribute. The study identified critical process parameters, performed a design of experiments, and developed a predictive model to define a design space relating PSD to operating conditions. Testing validated the model and provided samples for customers to evaluate formulation impact. The QbD approach improved process knowledge and control.
Similar to Quality Criteria Establishment for Dissolution of Ascorbic Acid from Sustained Release Pellets (20)
Agroindustrial Exploitation of the Mucilage Obtained from the Nopal Cactus Op...CrimsonpublishersNTNF
Agroindustrial Exploitation of the Mucilage Obtained from the Nopal Cactus Opuntia spp. Cultivated in Hydroponics by Romeo Rojas in Food Science Journal
Copper Nanoparticles and Antioxidant Stress: Problem Makers or Solvers?_ Cri...CrimsonpublishersNTNF
Copper nanoparticles (NPs) have various applications but also pose environmental concerns. They can act as both problem makers and problem solvers. As problem makers, copper NPs may accumulate in the environment and cause toxicity in plants and animals over the long term. However, they also show promise as problem solvers by demonstrating antibacterial properties useful for wound dressings, and potential antioxidant and antidiabetic effects. More research is still needed to fully understand the ecological effects of copper NP exposure and their long term impacts on human health before their widespread use can be considered safe.
Influence of Wall Material Composition on Microencapsulation Efficiency of Co...CrimsonpublishersNTNF
Influence of Wall Material Composition on Microencapsulation Efficiency of Cold Pressed Pumpkin Seed Oil by Freeze-Drying by Pelin Günç Ergönül in Food Science Journal
This document summarizes a study that investigated the potential cancer-preventative properties of purple sweet potato (PSP) in a mouse model of colorectal cancer. Mice fed diets supplemented with PSP flesh, skin, or anthocyanin-rich extract showed substantial reductions in polyp numbers of approximately two-thirds or more. The supplements were found to reduce DNA damage, inhibit NF-κB activation, and reduce expression of COX2 and iNOS, suggesting PSP may prevent colon cancer through multiple mechanisms including antioxidant effects and anti-inflammatory properties. The anthocyanins in PSP appear to be the active compounds responsible for these protective effects.
Phytochemical Composition and Nutritional Properties of Non-Diary Probiotic B...CrimsonpublishersNTNF
This document summarizes a research study on the phytochemical composition and nutritional properties of non-dairy probiotic beverages. Key findings include:
- Probiotic beverages were produced using extracts of various fruits, vegetables, and herbs. Phytochemical analysis found the presence of cardiac glycosides, alkaloids, flavonoids, and reducing sugars but not steroids, phenols, tannins, terpenoids, glycosides, or saponins.
- Proximate analysis found the beverages had high moisture content (over 96%), low levels of fat and carbohydrates, and no crude fiber. Crude protein and ash levels varied between samples.
- The
Extraction Efficiencies of Green Tea Bioactive Metabolites and their Anti-Dia...CrimsonpublishersNTNF
This document summarizes extraction methods for bioactive compounds from green tea and reviews the anti-diabetic effects of green tea extracts. It finds that extraction factors like temperature, time, solvent and solvent-solid ratio influence extraction yields. Various extraction techniques are compared. Studies show green tea extracts lower blood glucose and insulin resistance in mice and rats, likely due to compounds like catechins. Future research on improved extraction techniques could maximize green tea's anti-diabetic activity.
This document summarizes a study on risk factors for breast cancer in women in eastern China. The study found that breast cancer patients tended to be older, have higher BMI, be postmenopausal, and have a family history of breast cancer. Cancer patients consumed fewer soy products and more milk. No association was found between red meat consumption and cancer for the overall group. However, in urban areas, less red meat consumption was linked to higher cancer risk, possibly because urban residents choose lower-fat meat and better cooking methods. The relationship between diet, lifestyle factors, and cancer is complex, and red meat consumption alone may not determine cancer risk.
Physiological Determinants of Malnutrition in Elderly_ Crimson publishersCrimsonpublishersNTNF
This document discusses physiological determinants of malnutrition in the elderly. It begins by noting changes in body composition that occur with aging, including increases in fat mass and decreases in lean muscle mass. It then examines multiple factors that can cause poor appetite and reduced food intake in older adults, such as changes in taste/smell, dental issues, poverty, and medical/psychological conditions. It also discusses how conditions like cachexia and micronutrient deficiencies can negatively impact nutritional status. Finally, it notes how acute/chronic infections can increase metabolic demands and decrease the ability to meet those demands, potentially leading to malnutrition.
Effect of Storage on Protein Composition of Fermented Soybean (Glycine Max) S...CrimsonpublishersNTNF
Effect of Storage on Protein Composition of Fermented Soybean (Glycine Max) Seed by Bacillus Subtilli by Modupe Elizabeth Ojewumi in Food Science journal
A Simple, Practical Method for Measurement of Fat in Milk, Applied to Mid- to...CrimsonpublishersNTNF
A Simple, Practical Method for Measurement of Fat in Milk, Applied to Mid- to Late-Lactating Working Elephants in Myanmar by Ellen S Dierenfeld in Food science journal
Relationship between Vitamin D Status and Blood Pressure, Age, Physical Activ...CrimsonpublishersNTNF
Relationship between Vitamin D Status and Blood Pressure, Age, Physical Activity, and Nutritional Status in Saudi Males and Females by Tahani Aljurbua in Food Science_ Nutrition Open access Journal
The Menu affects everything in a restaurant; as our friend and FCSI consultant Bill Main says, “The Menu is your blueprint for profitability.”
Let’s start with the segment. What will be your marketing and brand positioning? It depends on what menu items you serve. What type of cooking methods and equipment will you use? GUEST EXPERIENCE = FACILITY (Space) DESIGN + MENU + SERVPOINTS™
W.H. Bender & Associates
408-784-7371
whb@whbender.com
www.whbender.com
San Jose, California
Panchkula offers a wide array of dining experiences. From traditional North Indian flavors to global cuisine, the city’s restaurants cater to every taste bud. Let’s dive into some of the best restaurants in Panchkula
A Review on Recent Advances of Packaging in Food IndustryPriyankaKilaniya
Effective food packaging provides number of purposes. It functions as a container to hold and transport the food product, as well as a barrier to protect the food from outside contamination such as water, light, odours, bacteria, dust, and mechanical damage by maintaining the food quality. The package may also include barriers to keep the product's moisture content or gas composition consistent. Furthermore, convenience is vital role in packaging, and the desire for quick opening, dispensing, and resealing packages that maintain product quality until fully consumed is increasing. To facilitate trading, encourage sales, and inform on content and nutritional attributes, the packaging must be communicative. For storage of food there is huge scope for modified atmosphere packaging, intelligent packaging, active packaging, and controlled atmosphere packaging. Active packaging has a variety of uses, including carbon dioxide absorbers and emitters, oxygen scavengers, antimicrobials, and moisture control agents. Smart packaging is another term for intelligent packaging. Edible packaging, self-cooling and self-heating packaging, micro packaging, and water-soluble packaging are some of the advancements in package material.
Heritage Conservation.Strategies and Options for Preserving India HeritageJIT KUMAR GUPTA
Presentation looks at the role , relevance and importance of built and natural heritage, issues faced by heritage in the Indian context and options which can be leveraged to preserve and conserve the heritage.It also lists the challenges faced by the heritage due to rapid urbanisation, land speculation and commercialisation in the urban areas. In addition, ppt lays down the roadmap for the preservation, conservation and making value addition to the available heritage by making it integral part of the planning , designing and management of the human settlements.
Cacao, the main component used in the creation of chocolate and other cacao-b...AdelinePdelaCruz
Cacao, the main component used in the creation of chocolate and other cacao-based products is cacao beans, which are produced by the cacao tree in pods. The Maya and Aztecs, two of the earliest Mesoamerican civilizations, valued cacao as a sacred plant and used it in religious rituals, social gatherings, and medical treatments. It has a long and rich cultural history.